

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 February 2024 (22.02.2024)



(10) International Publication Number
WO 2024/039689 A1

(51) International Patent Classification:

C07D 403/12 (2006.01) C07D 417/14 (2006.01)
C07D 405/12 (2006.01) C07D 471/04 (2006.01)
C07D 409/12 (2006.01) A61P 35/00 (2006.01)
C07D 413/12 (2006.01) A61K 31/422 (2006.01)
C07D 413/14 (2006.01) A61K 31/433 (2006.01)
C07D 417/12 (2006.01) A61K 31/427 (2006.01)

(21) International Application Number:

PCT/US2023/030294

(22) International Filing Date:

15 August 2023 (15.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/398,050 15 August 2022 (15.08.2022) US

(71) Applicant: **RECURSION PHARMACEUTICALS, INC.** [US/US]; 41 S. Rio Grande Street, Salt Lake City, UT 84101 (US).

(72) Inventors: **SAEED, Ashraf**; 41 S. Rio Grande, Salt Lake City, UT 84101 (US). **BAILEY, Chris**; 41 S. Rio Grande, Salt Lake City, UT 84101 (US). **BROOKS, Carl**; 41 S. Rio Grande, Salt Lake City, UT 84101 (US). **FALES, Kevin**; 41 S. Rio Grande Street, Salt Lake City, UT 84101 (US). **PAULSEN, Janet**; 41 S. Rio Grande Street, Salt Lake City, UT 84101 (US).

(74) Agent: **VOELKER, Alden, E.** et al.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: HETEROCYCLE RBM39 MODULATORS



(57) Abstract: Provided herein are compounds of formula (I) that modulate RBM39 and methods of using the compounds in RBM39-associated disorders, such as cancer (e.g., renal cell carcinoma).

WO 2024/039689 A1